Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer

Lawson Health Research Institute1 site in 1 country25 target enrollmentFebruary 2005

ConditionsProstate Cancer Bone Loss

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: Lawson Health Research Institute
Enrollment: 25
Locations: 1
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.

Registry

clinicaltrials.gov

Start Date

February 2005

End Date

February 2008

Last Updated

17 years ago

Study Type

Observational

Sex

Male

Investigators

Sponsor

Lawson Health Research Institute

Eligibility Criteria

Inclusion Criteria

•Age of 40 years or greater
•Diagnosis of advanced prostate cancer (ie: prostate-specific antigen \[PSA\] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone \[LHRH\] therapy)
•Willing and able to consent

Exclusion Criteria

•Metastatic disease to bone
•Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
•Renal failure (serum creatinine \> 200 umol/L)
•Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis)
•Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
•Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
•Gastrointestinal (GI) pathology (eg. malabsorption syndrome)
•Parathyroid disease